Evrysdi has proven efficacy in adults, children and babies two months and older, as shown in two pivotal clinical trials Roche is actively engaging with health authorities in the EU to achieve broad and rapid access for people with SMA More than 3,000 patients now treated with Evrysdi in clinical trial, compassionate use and real-world... Read more
Recommendation is based on the Phase III IMpower110 study showing that Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy If approved, Tecentriq could offer people with a specific type of lung cancer a chemotherapy-free option in the first-line treatment setting Basel, 26 March 2021 – Roche (SIX: RO, ROG;... Read more
Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger... Read more
With eight new configurations, cobas pro® integrated solutions offers labs greater flexibility to ramp up their testing capacity to adapt to evolving testing needs This will allow a greater number of patient samples to be processed faster By consolidating up to four analytical units on a single platform, testing efficiency in high-volume labs is increased... Read more
Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days The 2,400 mg and 1,200 mg doses tested in the phase III study had similar efficacy across all endpoints Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and... Read more
Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data Monitoring Committee (iDMC) No new safety signals were identified for tominersen in the iDMC’s review Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1... Read more
First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care Treating lung cancer early, before it has spread, may help prevent the disease from returning and therefore provide the best opportunity for a cure Data will be submitted to... Read more
cobas® pure integrated solutions brings together three diagnostic technologies1 on a single platform to optimise space and resources in small to medium laboratory settings With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests2 across a wide-range of disease areas... Read more
All proposals of the Board of Directors approved Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected 34th consecutive dividend increase to CHF 9.10 per share Basel, 16 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of... Read more
The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions Periodic assessments against emerging variants have... Read more